Skip to main content

Table 1 Cytokine secretion

From: Therapeutic potential of ixmyelocel-T, an expanded autologous multicellular therapy for treatment of ischemic cardiovascular diseases

 

HUVECs

IXT

HUVECs + IXT

Interleukin-3

181 ± 15

240 ± 20*

229 ± 24

Interleukin-6

9,610 ± 808

9,201 ± 7,368

59,567 ± 3,801***,‡

Interleukin-8

16,525 ± 1,697

36,998 ± 5,957**

35,128 ± 9,227

CXCL5

205 ± 34

7,893 ± 4,630

9,385 ± 1,710**

CCL1

83 ± 3

28 ± 8***

204 ± 39*,†

CCL7

67 ± 11

10,563 ± 1,748**

13,901 ± 3821**

MIF

3,765 ± 761

5,234 ± 1,556

5,364 ± 1,114

VEGF

15 ± 4

428 ± 275

95 ± 57

PDGF-BB

225 ± 29

34 ± 2***

1,065 ± 345*,†

EGF

171 ± 51

17 ± 5*

256 ± 74†

HGF

51 ± 8

5,752 ± 2,324*

271 ± 40**,†

PlFG

1,218 ± 210

1,123 ± 476†

2,648 ± 477*

Angiogenin

17,13 ± 237

33,102 ± 7,300**

8,722 ± 3,384*,†

Osteoprotegerin

434 ± 5

8,041 ± 5,992

2,049 ± 1,468

  1. Cytokines were quantified in supernatants from tumor necrosis factor alpha pretreated HUVECs, HUVECS co-cultured with ixmyelocel-T, and ixmyelocel-T (n ≥3). Values are presented as mean ± standard error of the mean relative to control. EGF, epidermal growth factor; HGF, hepatocyte growth factor; HUVEC, human umbilical vein endothelial cell; IXT, ixmyelocel-T; MIF, macrophage migration inhibitory factor; PDGF, platelet-derived growth factor; PlGF, placental growth factor; VEGF, vascular endothelial growth factor. *P <0.05, **P <0.01, ***P <0.001 versus HUVEC. † P <0.05, ‡ P <0.01 versus IXT.